The relationship between intact PTH and biointact PTH (1-84) with bone and mineral metabolism in pre-dialysis chronic kidney disease (CKD)

Clinical Biochemistry

Volumn 46, Issue 15, 2013, Pages 1405-1409

  O'Flaherty, D ^a   Sankaralingam, A ^a   Scully, P ^b   Manghat, P ^c   Goldsmith, D ^b   Hampson, G ^a,b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c DARENT VALLEY HOSPITAL   (United Kingdom)

Author keywords

Biointact PTH (1 84); Bone mineral density; Bone turnover; Chronic kidney disease; End stage renal disease; Intact PTH

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; PARATHYROID HORMONE; PHOSPHATE;

ACID PHOSPHATASE BLOOD LEVEL; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FOREARM; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY;

BIOINTACT PTH (1-84); BONE MINERAL DENSITY; BONE TURNOVER; CHRONIC KIDNEY DISEASE; END STAGE RENAL DISEASE; INTACT PTH;

ACID PHOSPHATASE; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BONE DEMINERALIZATION, PATHOLOGIC; BONE DENSITY; CALCITRIOL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; ISOENZYMES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHATES; RENAL DIALYSIS; SEVERITY OF ILLNESS INDEX;

EID: 84884350749     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.06.023     Document Type: Article

References (24)

1. Fukagawa M., Nakanishi S., Fujii H., Hamada Y., Abe T. Regulation of parathyroid function in chronic kidney disease (CKD). Clin Exp Nephrol 2006, 10(3):175-179.
2. Slatopolsky E., Brown A., Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 1999, 73:S14-S19.
3. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. National Kidney Foundation. Am J Kidney Dis Oct 2003, 42(4 Suppl. 3):1-201.
4. Moe S.M., Drüeke T.B., Block G.A., Cannata-Andía J.B., Elder G.J., Fukagawa M., et al. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl Aug 2009, 113:S1-S130.
5. Fernández-Martín J.L., Carrero J.J., Benedik M., Bos W.J., Covic A., Ferreira A., et al. COSMOS: the dialysisscenario of CKD-MBD in Europe. Nephrol Dial Transplant Nov 19 2012, [Epub ahead of print].
6. Moe S., Drueke T., Cunningham J., Goodman W., Martin K., Olgaard K., et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006, 69(11):1945-1953.
7. Garrett G., Sardiwal S., Lamb E.J., Goldsmith D.J. PTH - a particularly tricky hormone: why measure it at all in kidney patients?. Clin J Am Soc Nephrol Feb 2013, 8(2):299-312.
8. Lepage R., Roy L., Brossard J.H., Rousseau L., Dorais C., Lazure C., et al. A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 1998, 44(4):805-809.
9. Brossard J.H., Lepage R., Cardinal H., Roy L., Rousseau L., Dorais C., et al. Influence of glomerular filtration rate on non-(1-84) parathyroid hormone (PTH) detected by intact PTH assays. Clin Chem 2000, 46(5):697-703.
10. Nguyen-Yamamoto L., Rousseau L., Brossard J.H., Lepage R., D'Amour P. Synthetic carboxyl-terminal fragments of parathyroid hormone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTH-related peptide receptor. Endocrinology 2001, 142(4):1386-1392.
11. Archibald G., Bartlett W., Brown A., Christie B., Elliott A., Griffith K., et al. UK consensus conference on early chronic kidney disease - 6 and 7 February 2007. Nephrol Dial Transplant 2007, 22(9):2455-2457.
12. Joseph F., Ahmad A.M., Ul-Haq M., Durham B.H., Whittingham P., Fraser W.D., et al. Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis. J Bone Miner Res 2008, 23(5):721-729.
13. Manghat P., Fraser W.D., Wierzbicki A.S., Fogelman I., Goldsmith D.J., Hampson G. Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int Nov 2010, 21(11):1853-1861.
14. Brossard J.H., Cloutier M., Roy L., Lepage R., Gascon-Barre M., D'Amour P. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrinol Metab 1996, 81(11):3923-3929.
15. Nigwekar S.U., Bhan I., Thadhani R. Ergocalciferol and cholecalciferol in CKD. Am J Kidney Dis 2012, 60(1):139-156.
16. Hecking M., Kainz A., Bielesz B., Plischke M., Beilhack G., Horl W.H., et al. Clinical evaluation of two novel biointact PTH(1-84) assays in hemodialysis patients. Clin Biochem 2012, 45(18):1645-1651.
17. Souberbielle J.C., Roth H., Fouque D.P. Parathyroid hormone measurement in CKD. Kidney Int 2010, 77(2):93-100.
18. Slatopolsky E., Finch J., Clay P., Martin D., Sicard G., Singer G., et al. A novel mechanism for skeletal resistance in uremia. Kidney Int 2000, 58(2):753-761.
19. Coen G., Bonucci E., Ballanti P., Balducci A., Calabria S., Nicolai G.A., et al. PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis 2002, 40(2):348-354.
20. Monier-Faugere M.C., Geng Z., Mawad H., Friedler R.M., Gao P., Cantor T.L., et al. Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int 2001, 60(4):1460-1468.
21. Nickolas T.L., Stein E., Cohen A., Thomas V., Staron R.B., McMahon D.J., et al. Bone mass and microarchitecture in CKD patients with fracture. J Am Soc Nephrol 2010, 21(8):1371-1380.
22. Iimori S., Mori Y., Akita W., Kuyama T., Takada S., Asai T., et al. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients - a single-center cohort study. Nephrol Dial Transplant 2012, 27(1):345-351.
23. Tomida K., Hamano T., Mikami S., Fujii N., Okada N., Matsui I., et al. Serum 25-hydroxyvitamin D as an independent determinant of 1-84 PTH and bone mineral density in non-diabetic predialysis CKD patients. Bone 2009, 44:678-683.
24. OTT S.M. Review article: bone density in patients with chronic kidney disease stages 4-5. Nephrology 2009, 14:395-403.